News & Updates

Treatment with the combination of the small molecule Janus kinase 1/2 inhibitor baricitinib plus phototherapy may help reduce disease activity and induce repigmentation in adults with extensive and active nonsegmental vitiligo, according to the results of a phase II study.

A new patch that adheres to the skin and delivers two active ingredients holds promise in the treatment of psoriasis, reducing the need to apply topical medications to once a day and potentially improving adherence.

The Metagenome-Assembled Genome Inventory for Children (MAGIC) database, which contains 20,172 global gut metagenomes from humans aged 0–7 years, characterizes the bacteriome and virome diversity of the global gut microbiome in early life.

A large cohort study suggests that for patients with acne who received an isotretinoin treatment course, the cumulative dosage taken, rather than the daily dose, is a key factor for reducing the risk of relapse and treatment retrial.

New drug applications approved by US FDA as of 16-31 December 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

QX004N, a humanized IgG1λ monoclonal antibody targeting IL-23, is superior to placebo in the treatment of patients with moderate to severe plaque psoriasis, according to a phase I trial.

New drug applications approved by US FDA as of 1-15 December 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.